\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{https://ijrps.com}{\color{blue}\underline{\smash{https://ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage{float}

\begin{document}


\def\RunningAuthor{Faten Q. Ibraheem and Anmar A. Abdelrazzaq}
\firstPage{2300}
\articleType{Original Article}
\receivedDate{09.04.2019}
\acceptedDate{20.07.2019}
\revisedDate{16.07.2019}
\journalVolume{10}
\journalIssue{3}
\journalDoi{ijrps.v10i3.1467}
\copyrightYear{2019}
\def\authorCount{2}
\def\affCount{1}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{Studying the effect of variables on baclofen floating microsponge}
\author{Faten~Q.~Ibraheem\textsuperscript{*}, 
            Anmar~A.~Abdelrazzaq~\\[5pt]{Department of Pharmaceutics, College of Pharmacy\unskip, University of Israa, Baghdad, Iraq}}

\begin{abstract}
The aim of the present work was to develop a microsponge delivery system of baclofen to control its release and thereby reducing dosing frequency and enhancing patient compliance. The microsponge was produced by oil in oil emulsion solvent diffusion method. The effects of drug/polymer ratio, stirring time and type of Eudragit polymer on the physical characteristics of microsponges were investigated. The prepared microsponges was characterized for production yield (PY), loading efficiency (LD), particle size, surface morphology, and \textit{in vitro} drug release. The results showed that the microsponge formula with Eudragit RS100 had optimum physical properties with PY \% equal to 97 \%, and LD \% equal to 81\% and controlled drug release (75\% of drug release in 8 hours) when compared with other formulas and pure BFN. Therefore, the non-aqueous emulsion solvent diffusion method is a promising method to produce baclofen microsponges.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Baclofen,\newline microsponge,\newline delivery system,\newline controlled released
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Faten~Q.~Ibraheem~\\ Phone:\ ~\\  Email:\ fatenalatraqchi@gmail.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{https://ijrps.com}{https://ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Conventional tablet dosage form is administered several times a day, to avoid unnecessary repetitive management, a higher treatment cost and other undesirable characteristics of the conventional dosage forms, controlled release systems were designed, as they require less frequent drug intake, more therapeutic effects and less side effects. These dosage forms are designed to release medication continuously over a long period of time \unskip~\citep{579182:13402487}. Gastro-retentive delivery systems are designed to be kept in the stomach for a long time and release their active ingredients thus enabling continuous and long-lasting input of the drug to the top of the GIT \unskip~\citep{579182:13402476}. There are two types of designing a floating-dose model. These are single-unit systems and multiple-unit systems \unskip~\citep{579182:13402475,579182:13402469}. One of the new ways of the gastro-retentive dosage form is the floating microsponge. It significantly increases the residence time of medication in the stomach, improves bioavailability, improves patient compliance by reducing frequency doses, reduces drug waste \unskip~\citep{579182:13402484}. The microsponges are small spherical particles consisting of innumerable interconnected spaces under a non-folding structure with a large porous surface through which active components are released in a controlled manner. Microsponge could encapsulate a wide range of hydrophilic and hydrophobic drugs \unskip~\citep{579182:13402478}. The solubility of BFN decreases with increasing pH, having maximum solubility at pH 1.2, which equal to 26 mg/ml. It has short plasma half-life, which is about 2{\textendash}4 hr. \unskip~\citep{579182:13402467}. Baclofen has a narrow absorption window in the small intestine because, on arrival to the colon, the absorption becomes low or nonexistent \unskip~\citep{579182:13402485}. The primary objective of the present investigation was to develop and optimize the BFN floating microsponge formula to control the release rate of the drug and subsequent evaluation of different variables affecting it.
    
\section{Materials and Methods}
 Baclofen (Hyperchem company, China), Eudragit polymers RS100 and RL100 (Rhom pharma, Germany), liquid paraffin (Solvochem company, United Kingdom), n-hexane (Chemlab, Belgium).

\textbf{Preparation of BFN microsponges}

The BFN microsponge formulas were produced by oil in oil emulsion solvent diffusion technique. The internal phase consisted of polymer in   the organic solvent. Then the BFN was added gradually to the internal phase with the addition of magnesium stearate, and the mixture stayed in the ultrasonic bath for 5 minutes to obtain a homogenous dispersion. Magnesium stearate was added as a stabilizer for reduction of particle aggregation. Then, the mixture was poured gradually into liquid paraffin and stirred by using a magnetic stirrer. The oil in oil emulsion formed was stirred for a different duration at different stirring speed. During the stirring period, the solvent diffused into liquid paraffin will be evaporated, leaving spherical porous particles. The solidified microsponges were filtered by using Whatman filter paper and washed five times with 60 ml of n-hexane, dried at room temperature for 12 h and stored in a desiccator for further investigations \unskip~\citep{579182:13402483}. 

\textbf{Characterization and evaluation of BFN microsponge}

\textbf{Determination of the percent production yield (PY)}

The percent production yield of the prepared BFN microsponge formula was determined by dividing the final weight of microsponge formula on the initial weight of the raw material multiplied by 100 \unskip~\citep{579182:13402474}.
\begin{eqnarray*}\begin{array}{l}PY\%=\frac{Practical\;weight\;of\;microsponge}{Theoretical\;weight\;(polymer\;+\;drug)}\\x\;100\end{array} \end{eqnarray*}
\textit{\textbf{Determination of percent loading efficiency (LD)}}

The drug content in all prepared microsponge formulas was determined spectrophotometrically, in which 10 mg of the prepared microsponge formula was dissolved in 100 ml of 0.1N HCl (pH 1.2) and kept for 12 hr. The solution was diluted suitably with 0.1N HCl and analyzed spectrophotometrically at \ensuremath{\lambda } max of BFN. The drug content was calculated from the calibration curve equation and expressed as the loading efficiency (\%) \unskip~\citep{579182:13402482}.
\begin{eqnarray*}\begin{array}{l}LD\%=\frac{Actual\;weight\;of\;Baclofen\;in\;microsponge}{Theoretical\;weight\;of\;Baclofen}\\\ast100\end{array} \end{eqnarray*}
\textbf{Particle size measurement}

The particle size of microsponge was determined using an optical microscope. Calibration of the eyepiece micrometer with a stage micrometer was done. A minute quantity of microsponges was spread on a clean glass slide, the particle diameters of around 100 microsponges were measured randomly, and the average particle size of BFN microsponge was determined \unskip~\citep{579182:13402473}.
\begin{eqnarray*}D\;(average)\frac{\sum nd}{\sum n} \end{eqnarray*}
Where n = number of microsponge observed, d = middle value (\ensuremath{\mu }m), D is the average diameter of particles (\ensuremath{\mu }m).

\textbf{Buoyancy study}

Buoyancy study is done by placing the microsponge formula in 100 ml beaker of 0.1N HCl and remained for 12 hr. the floating and sinking particles filtered and left to dry overnight, the \% buoyancy calculated by dividing the weight ratio of the floating particles to the sum of floating and sinking particles.

\textbf{Scanning electron microscope (SEM) study}

The surfaces morphology of the microsponge formula was analyzed by SEM. Sprinkling the microsponge on adhesive tape stuck to aluminum stub and by using a gold sputter module for coating this stub with gold, and then this coated sample was scanned, and photomicrographs were taken by SEM \unskip~\citep{579182:13402488}.

\textbf{In-vitro drug release studies of microsponge formulations}

Baclofen microsponge formulas were subjected to an in-vitro drug releasee study by using dissolution testing apparatus type ӀӀ (paddle). The dissolution test was carried out, utilizing 900 ml of 0.1N HCl (pH 1.2). A specified weight of microsponge corresponding to 15 mg of BFN was taken and by using semipermeable membrane rotated at 50 rpm at 37 \ensuremath{\pm} 0.5 0C. A sample of 5 ml was collected every hour for 10 hrs and immediately was displaced with 5 ml of fresh dissolution medium (0.1N HCl) for preserving sink conditions, after that the sample was filtrated through 0.45 \ensuremath{\mu }m filter syringe. The absorbance of the filtrate was measured by UV spectrophotometer at the corresponding \ensuremath{\lambda }\ensuremath{_{max}} of BFN \unskip~\citep{579182:13402471,579182:13402489}. This procedure was done in triplicate for each formula to take the mean value.

\textbf{Fourier transforms infrared (FTIR) analysis}

Infrared spectroscopy was conducted using FTIR spectrophotometer (Biotech, England) and the spectrum was recorded in the wavelength region of (4000 - 400) cm\ensuremath{^{-1}}. The procedure consisted of dispersing the sample (drug alone, selected polymer alone, physical mixture of drug with polymer and the optimized formula) in the KBr disc to certify compatibility \unskip~\citep{579182:13402468}.

\textbf{Differential scanning calorimetric (DSC) analysis}

DSC analysis of pure drug, selected polymer, physical mixture of drug and selected polymer and the optimized microsponge formula were done to indicate thermal compatibility between drug and polymer during the formulation of microsponges and to assess the crystalline state of the drug \unskip~\citep{579182:13402470}.

\textbf{Statistical analysis}

The results of the experiments were given as a mean of three samples \ensuremath{\pm} standard deviation. Statistical analysis of data was performed using SAS (Statistical Analysis System - version 9.1) using ANOVA test to assess significant differences among means, P \textless\ 0.05 was considered statistically significant.
    
\section{Results and Discussion}
\textit{\textbf{Effect of the drug: Polymer ratio on the microsponges}}

The drug-polymer ratio had a considerable effect on the nature of microsponges, as shown in Table~\ref{tw-eab419c92a8d}. It was indicated that increasing the drug: polymer ratio to certain limit increased the PY and LD. Since the available polymer was sufficient to encapsulate more amount of drug resulted in high LD.


\begin{table*}[!htbp]
\caption{\boldmath {Effect of Drug Polymer Ratio on Physical Properties of the Microsponge } }
\label{tw-eab419c92a8d}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1416\linewidth-2\tabcolsep}p{\dimexpr.16569999999999997\linewidth-2\tabcolsep}p{\dimexpr.17270000000000003\linewidth-2\tabcolsep}p{\dimexpr.16\linewidth-2\tabcolsep}p{\dimexpr.1669\linewidth-2\tabcolsep}p{\dimexpr.1931\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor} Formulas & Drug: polymer ratio & Polymer type & PY \% \ensuremath{\pm} SD & LD \% \ensuremath{\pm} SD & Mean particle size (\ensuremath{\mu }m) \ensuremath{\pm} SD\\
\tblmidrule 
BF1 &
  1:1 &
  Eudragit RS100 &
  89.66\ensuremath{\pm}0.577 &
  66.831\ensuremath{\pm}0.359 &
  47.7\ensuremath{\pm}1.7\\
BF2 &
  2:1 &
  Eudragit RS100 &
  90.834\ensuremath{\pm}0.213 &
  70.812\ensuremath{\pm}1.35 &
  60.3\ensuremath{\pm}0.8\\
BF3 &
  3:1 &
  Eudragit RS100 &
  93.83\ensuremath{\pm}0.288 &
  75.728\ensuremath{\pm}1.09 &
  68.5\ensuremath{\pm}0.8\\
BF4 &
  1:1 &
  Eudragit RL100 &
  87.43\ensuremath{\pm}1.15 &
  66.57\ensuremath{\pm}0.14 &
  50\ensuremath{\pm}0.17\\
BF5 &
  2:1 &
  Eudragit RL100 &
  89.665\ensuremath{\pm}0.47 &
  71.35\ensuremath{\pm}0.07 &
  57.2\ensuremath{\pm}1.7\\
BF6 &
  3:1 &
  Eudragit RL100 &
  95.31\ensuremath{\pm}1.02 &
  76.03\ensuremath{\pm}1.15 &
  70.4\ensuremath{\pm}0.8\\
BF7 &
  4:1 &
  Eudragit RS100 &
  83.73\ensuremath{\pm}0.23 &
  62.452\ensuremath{\pm}0.594 &
  72.53\ensuremath{\pm}1\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
Further increase in drug to polymer ratio have reverse effect on both the PY and LD as shown in BF7, the reason for decrease in both the PY and LD with increasing drug to polymer ratio is due to the amount of polymer was not sufficient to encapsulate all amount of drug \unskip~\citep{579182:13402480}.

It was observed that as the ratio of drug to polymer was increased. The particle size increased due to increase the viscosity of the internal phase and therefore, will be hardly broken into small droplets \unskip~\citep{579182:13402486}. It was detected that the formulation of microsponge using Eudragit RS 100 showed higher PY and LD. This may be due to the differences between these polymers, Eudragit RS100 contains 5\% quaternary ammonium group which is less than that contained in Eudragit RL100 (10\%), and therefore these polymers differ in their permeability. Moreover, Eudragit RS100 preferable over Eudragit RL100 in microsponges preparation using oil in oil emulsion solvent diffusion method \unskip~\citep{579182:13402490}. Statistically, this increment in the PY, LD, and mean particle size with the increasing drug: polymer ratio was significant (P \textless\ 0.05) when using a one-way ANOVA test.

\textbf{Effect of internal phase volume on } \textit{\textbf{\space }} \textbf{the BFN microsponges}

The amount of solvent volume needs to be controlled within an appropriate range during microsponge preparation due to its effect not only on the formation of emulsion droplets at the initial stage but also on the solidification of drug and polymer in the droplets. 

BF15 and BF17 fabricated with 10ml acetone, resulted in finely dispersed spherical emulsion droplets during agitation, but as the stirring was discontinued emulsion droplets adhered together and coalesce. Consequently, no microsponges could be formed with an increasing volume of acetone to 10 ml \unskip~\citep{579182:13402477}.

The role of the solvent was acting as porogen (pore-forming agent) since the evaporation of solvent lead to formation of pores into which the drug is loaded, and this was the reason for increasing the LD \unskip~\citep{579182:13402479} associated with increasing the volume of internal phase solvent from 5 ml to 7.5 ml. Larger particle size was associated with lower internal phase volume (5 ml) which may be to high viscous phase would be difficult to split the droplets to smaller ones when poured into the external paraffin phase. The effect of acetone volume on the particle size was shown in Figure~\ref{f-d63944a6e5da}. The increase solvent volume from 5 ml to 7.5 ml showed a significant effect on LD and mean particle size as p-value {\textless}0.05 when using the one-way ANOVA.


\bgroup
\fixFloatSize{images/f30ac8e6-4e66-4d39-9e11-bf86dabd00de-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/f30ac8e6-4e66-4d39-9e11-bf86dabd00de-upicture1.png}{\includegraphics{images/f30ac8e6-4e66-4d39-9e11-bf86dabd00de-upicture1.png}}{}
\makeatother 
\caption{\boldmath {Histogram showing effect of internal phase volume on mean particle size. Effect of stirring speed on BFN \textit{microsponges}}}
\label{f-d63944a6e5da}
\end{figure}
\egroup
The dispersion of the internal phase of drug and polymer into the droplets in the external phase depended on the agitation speed of the systems. As agitation speed increased, the size of microparticles was reduced due to rapid division of the formed droplets at high stirring speed, which may have less chance of coalescing into bigger droplets with production of more uniform and spherical particles while at lower stirring speed particles suffered from coalescence and aggregation \unskip~\citep{579182:13402472}. The microsponges formulated with 1500 rpm had higher LD \%. So, it was selected as the optimum stirring speed. Statistically, the effect of stirring speed on the PY \% was non- significant but produces a significant effect (P-value \textless\ 0.05) on both the LD\% and mean particle size. 

\textbf{Effect of stirring duration on the BFN microsponges}

To find the most appropriate stirring time for fabrication of BFN microsponges, different stirring duration was used 0.5 hr., 1 hr. And 2hr. in BF12, BF1 and BF13 respectively, the results are listed in Table~\ref{tw-bd33849c2aab} . Stirring duration of 2h in BF13 resulted in low PY\% and LD \% due to adherence of polymer to beaker during fabrication of microsponges, in addition, a longer time of stirring there was more chance for the drug to be leached. Accordingly, it was adopted that the optimum stirring time is 1 hr. Since 0.5 hr. The stirring duration was associated with lower PY\% and LD\%. This finding was similar to previously reported by \unskip~\citep{579182:13402481}.

Increase stirring duration from 0.5 hr. to 1 hr. Produced a significant effect on PY\% and LD\% as P value \textless\ 0.05 when using the one-way ANOVA test.


\begin{table*}[!htbp]
\caption{\boldmath {Effect of Stirring Duration on Physical Prosperities of Microsponges} }
\label{tw-bd33849c2aab}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0924\linewidth-2\tabcolsep}p{\dimexpr.0924\linewidth-2\tabcolsep}p{\dimexpr.1034\linewidth-2\tabcolsep}p{\dimexpr.1028\linewidth-2\tabcolsep}p{\dimexpr.0931\linewidth-2\tabcolsep}p{\dimexpr.1284\linewidth-2\tabcolsep}p{\dimexpr.1041\linewidth-2\tabcolsep}p{\dimexpr.0868\linewidth-2\tabcolsep}p{\dimexpr.0888\linewidth-2\tabcolsep}p{\dimexpr.10780000000000001\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Formula & drug: polymer ratio & type of polymer & acetone \mbox{}\protect\newline (ml) & paraffin \mbox{}\protect\newline (ml) & stirring speed(rpm) & stirring duration(hr.) & PY\% \ensuremath{\pm}SD & LD\% \ensuremath{\pm}SD & Mean particle size\ensuremath{\pm}SD  \mbox{}\protect\newline (\ensuremath{\mu}m)\\
\tblmidrule 
BF1 &
  1:1 &
  Eudragit RS100 &
  5 &
  100 &
  1500 &
  0.5 &
  77.6\ensuremath{\pm} 0.51 &
  60.83\ensuremath{\pm} 3.05 &
  42.83\ensuremath{\pm} 0.61\\
BF12 &
  1:1 &
  Eudragit RS100 &
  5 &
  100 &
  1500 &
  1 &
  89.66\ensuremath{\pm} 0.577  &
  66.831\ensuremath{\pm} 0.35 &
  47.7\ensuremath{\pm} 1.7\\
BF13 &
  1:1 &
  Eudragit \mbox{}\protect\newline  RS100 &
  5 &
  100 &
  1500 &
  2 &
  80.9\ensuremath{\pm} 0.17 &
  63.686\ensuremath{\pm} 1.8 &
  47.36\ensuremath{\pm} 1.7\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Effect of solvent type on BFN microsponges}

Acetone was the preferable solvent for the oil in oil emulsion solvent diffusion method due to its dielectric constant (20.7), so it was poorly miscible with paraffin, that would lead to the slow diffusion of the solvent out of the emulsion droplets to the external paraffin medium, resulted in slow precipitation of polymer matrix, and subsequent separation of a microsphere with a spongy structure \unskip~\citep{579182:13402490}. Microsponge preparation by using acetone gave higher PY\%, LD\% than that of ethanol, as illustrated in Figure~\ref{f-a842b1a479f2}.


\bgroup
\fixFloatSize{images/938e1a9f-d41b-4b4d-a505-9caac6333ddd-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/938e1a9f-d41b-4b4d-a505-9caac6333ddd-upicture2.png}{\includegraphics{images/938e1a9f-d41b-4b4d-a505-9caac6333ddd-upicture2.png}}{}
\makeatother 
\caption{\boldmath {Effect of solvent type on physical properties of micro-sponges}}
\label{f-a842b1a479f2}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/11bbba9c-29cf-4de0-bb39-ab4a929ff31d-upicture3.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/11bbba9c-29cf-4de0-bb39-ab4a929ff31d-upicture3.png}{\includegraphics{images/11bbba9c-29cf-4de0-bb39-ab4a929ff31d-upicture3.png}}{}
\makeatother 
\caption{\boldmath {Dissolution profile of BFN from different microsponge formula in 0.1N HCl (pH1.2) at 37\text{\textordmasculine}C }}
\label{f-28f8df377a94}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/8e9ae3f6-3636-4119-a82e-f3a99ef00d7c-upicture4.png}
\begin{figure*}[!htbp]
\centering \makeatletter\IfFileExists{images/8e9ae3f6-3636-4119-a82e-f3a99ef00d7c-upicture4.png}{\includegraphics{images/8e9ae3f6-3636-4119-a82e-f3a99ef00d7c-upicture4.png}}{}
\makeatother 
\caption{\boldmath {SEM of the selected microsponge formula BF14 at (Left) 310 X magnification and (right) 270 X magnification}}
\label{f-3eb38f264338}
\end{figure*}
\egroup
\textbf{In- vitro drug release study of microsponges}

Dissolution was done for different microsponge formulas and pure BFN, as illustrated in Figure~\ref{f-28f8df377a94}. Faster and greater drug release was noticed from BF16 than that of BF14 which may be related to higher drug amount compared to the amount of polymer which resulted in more porosity and consequently, more drug release was obtained.

The amount of polymer available per microsponge showed a realistic effect on drug release. So, as the amount of polymer became equal to the amount of drug, increase in the thickness of the polymer matrix was obtained that led to longer diffusion path and ultimately to decreased drug release.

BF14 was determined as the optimum formula because it showed control drug release (75\% of drug release in 8 hr.), acceptable PY and LD, so it was subjected to further investigation.

\textbf{Buoyancy studies}

The In-vitro buoyancy test was carried out to investigate the buoyancy of prepared floating microsponges. The BF14 showed the good floating ability of 88.11\%.

\textbf{Evaluation of the shape and surface morphology by scanning electron microscope (SEM)}

The SEM result of the selected microsponge formula showed (Figure~\ref{f-3eb38f264338}) a spherical nature of the microsponge, uniform size with sufficient pores that loaded with the drug.

\textbf{Fourier transforms infrared spectroscopy}

The spectrum of pure BFN showed characteristic peaks at 1398 cm\ensuremath{^{-1}} (O-H bending), 1244cm\ensuremath{^{-1 }}(C-O stretching), 831cm\ensuremath{^{-1}} (C-Cl stretching), which considered as fingerprint of BFN, the FTIR of BFN also showed broad peak at 2590 and extended up to 3100cm\ensuremath{^{ -1}}(O-H of alcohol and carboxylic acid stretching). The spectrum of the physical mixture was as that of the drug, indicating no chemical interaction or complexation. The spectrum of the selected formula BF14 exhibited similar peaks, no appearance or disappearance of peaks and/or shift of their positions and therefore BFN was apparently stable in the microsponges.

\textbf{Differential scanning electron microscopy (DSC)}

The thermal behavior of pure BFN showed a sharp endothermic peak at 213.24\ensuremath{^\circ}C corresponding to BFN melting temperature with the onset of the peak at 208.74\ensuremath{^\circ}C and end set at 217.35\ensuremath{^\circ}C. This indicates that the drug was in the pure crystalline state.

The thermogram of the physical mixture of BFN and Eudragit RS100 at equal ratio (1:1), and the selected BFN microsponge formula (BF14) exhibited endothermic peaks at 211.84 and 192.94 \ensuremath{^\circ}C respectively.
    
\section{Conclusion}
Microsponges of BFN were successfully formed by the non-aqueous emulsion solvent diffusion method, and the microsponge formulas exhibited excellent floating ability that remained buoyant and extended drug release successfully.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
